EMR

Business Context and Reporting Period

Emerson Electric Co. (EMR) filed a Form 8-K on January 27, 2025, reporting events occurring on January 26, 2025. The filing announces the entry into a definitive Agreement and Plan of Merger to acquire the remaining outstanding shares of Aspen Technology, Inc. (AspenTech) that Emerson does not already own.

Key Financial Metrics and Transaction Terms

• Offer Price: $265.00 per share in cash, without interest.
• Current Ownership: Emerson currently owns approximately 57.4% of AspenTech's issued and outstanding shares.
• Termination Fee: AspenTech has agreed to pay Emerson a termination fee of $221,000,000 under specific circumstances, such as a change in recommendation by AspenTech's board or special committee.
• Offer Duration: The tender offer will remain open for a minimum of 20 business days, with potential extensions up to an "Extension Deadline" of April 26, 2025.

Note: This filing is a Current Report (8-K) regarding a material agreement and does not contain Emerson's periodic financial statements (revenue, profit, cash flow, or debt levels) for the reporting period.

Material Changes and Transaction Structure

The primary material change is the initiation of a two-step acquisition process:

1. Step 1 (Tender Offer): Emerson's subsidiary (Purchaser) will commence a tender offer to purchase all remaining shares of AspenTech common stock at $265 per share.
2. Step 2 (Merger): Following the tender offer, Purchaser will merge with and into AspenTech under Section 251(h) of the Delaware General Corporation Law. Remaining shares will be converted into cash equal to the Offer Price.

Key Conditions: The transaction is subject to customary conditions, including a non-waivable requirement that shares representing at least one more share than 50% of the total outstanding shares (excluding shares owned by Emerson and insiders) are validly tendered and not withdrawn.

Guidance, Risks, and Contingencies

The filing includes extensive forward-looking statements and risk factors. Key contingencies and risks include:

• Regulatory Approval: The transaction may be prohibited, delayed, or conditioned by governmental entities.
• Competing Offers: The possibility of a superior proposal emerging.
• Integration Risks: Uncertainty regarding the realization of synergies, retention of key personnel, and integration costs.
• Termination Rights: Either party may terminate the agreement if the offer is not consummated by April 26, 2025, or if specific conditions are not met.
• Legal and Operational Risks: Potential litigation, cybersecurity threats, and disruptions to business operations during the pendency of the transaction.

Investor Verification Checklist

• Verify the final tender offer materials (Schedule TO and Offer to Purchase) once filed with the SEC for definitive terms.
• Monitor the status of the "Unaffiliated Tender Condition" to ensure the required majority of minority shares are tendered.
• Track regulatory approval timelines and any conditions imposed by antitrust or other governmental bodies.
• Review the full text of the Merger Agreement (Exhibit 2.1) for detailed representations, warranties, and covenants.
• Assess the impact of the $221 million termination fee provision on potential deal break scenarios.